Press & News

People are different and so is their cancer, patients should be treated individually.

2cureX AB nominates Dr. Michael Schaefer to the Board of Directors

May 12, 2022

IR

Regulatory

Dr. Michael Schaefer has been proposed as new member of the Board of Directors of 2cureX AB. His experience in oncology, lab automation and Asian markets will be of great value at this stage of the company expansion.

Dr. Schaefer is biologist and chemist by Mainz University (Germany). His professional career started at E. Merck Darmstadt, in Microbiology and Cell Diagnostics. He moved to Bayer Diagnostics as Marketing Director for Haematology and Lab Information Systems, leading the company to a top position in the market. Appointed Regional Director in South-East Asia in 1993, based in Singapore, he grew the turnover of the company by a factor of five in the following four years.

He joined Sysmex Corporation in 1997 to lead the operations in EMEA, bringing the company over the following twenty years to the European market leader position in lab haematology, coagulation and urinalysis, with sales of about half a billion EUR. In the process, he established and was Director of most of the close to thirty Sysmex affiliates in EMEA.

In his last years at Sysmex he was appointed Executive VP of Sysmex Corporation, Kobe, Japan, in charge of New Business Development, where he led three major acquisition projects and defined the company Global strategy in the Oncology area.

Povl-André Bendz, Chairman of the Board at 2cureX AB: “We are very pleased that Dr. Schaefer agreed to be nominated to our Board of Directors. His experience in oncology, lab automation and Asian markets fits very well to the current expansion of 2cureX, and we are looking forward to the outcome of the Annual General Meeting to welcome him on board.

At the same time, I would like to thank Jørgen Drejer, who has requested to step down as a member of the Board, for his contribution since he joined five years ago. The company has greatly benefitted from his experience and insights in the transition from the pre-IPO stage to being a listed company”.